A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

NCT01754116 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG: GSK1265744 30 mg oral
DRUG: Midazolam 3 mg oral + GSK1265744 30mg oral
DRUG: GSK1265744 400 mg (200 nm)
DRUG: GSK1265744 400 mg (1 micro m)
DRUG: GSK1265744 400 mg (5 micro m)

Sponsor

ViiV Healthcare

Collaborators

[object Object]